Cytel is one of the leading global providers of clinical trial design SaaS software, biometric services and advanced analytics, focusing on optimising clinical trials and helping pharmaceutical companies to unlock the full potential of their clinical and real-world data.

Cytel is recognised as an industry pioneer of adaptive clinical trials and other innovative quantitative methods, helping biotech and pharmaceutical companies to reduce risk, increase R&D productivity and support medical innovation, improving speed, productivity and efficiency of clinical trials. Headquartered in Waltham, Massachusetts, Cytel has more than 1,500 employees across North America, Europe and Asia. Cytel’s software and services are used by over 500 life sciences customers, including the world’s 30 top pharmaceutical companies, as well as regulatory bodies such as the FDA.

The Company was founded over 30 years ago by renowned statisticians Cyrus Mehta and Nitin Patel, thought-leaders in statistical science, and Cytel has since then continued to providing life sciences companies with cutting-edge clinical trial optimisation technologies to help harnessing the full value of their clinical and real-world data.

Nordic Capital acquired Cytel in 2021 in partnership with Astorg. Building on Cytel’s advanced software platform and leading biometrics services offerings, Nordic Capital will invest in the continued development of the business and its software with the ambition to actively support and accelerate Cytel’s next phase of growth and innovation.


Sector Icon

Tech & Payments

Sector Icon


Key Information

Revenues Icon

Revenues 2021*

EUR 220 million

Employees Icon



Ownership Icon


Nordic Capital Fund X

Head Office Icon

Head office

Waltham, Massachusetts, USA

Investment Icon

Investment date